Navigation Links
AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy

Efficacy and Safety of Gene Therapy in Lipoprotein Lipase Deficiency Established

Amsterdam, The Netherlands - May 31, 2007 - Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, reported positive Phase I/II clinical trial results with its lead product AMT-010 (now referred to as AMT-011) in Complete Lipoprotein Lipase (LPL) deficient patients at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle. The study's lead investigator is Erik S.G. Stroes, MD, PhD, from the University of Amsterdam Medical Center in The Netherlands.

Ronald Lorijn, CEO of AMT, said, "We believe these excellent results may represent an important milestone for the entire field of gene therapy and for the many patients who today cannot be treated. Our clinical success and the breakthrough in our production platform place us squarely at the forefront of the gene therapy field that is finally coming into its own."

AMT's products rely on a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Study design

The primary goal of the study presented at the ASGT was to investigate if AMT-010 reduces the elevated triglyceride (fat) levels and the associated risk of pancreatitis in Complete LPL deficient patients. The study design was an eight-patient open label dose-escalating study (low and mid dos e). The study was started in August 2005 and finalized in April 2007, and in effect demonstrates the safety and efficacy of AMT-010. All patients are now taking part in a follow-up trial, which will last for 12 months.

Efficacy

The primary endpoints of the study were either median fasting plasma triglyceride (TG) levels after administration of AMT-010 equal to or less than 10 mmol/L, or a 40% reduction in median fasting plasma TG after administration on top of a fat-free diet. For all subjects a substantial reduction of median TG levels was observed. Three patients (one from the low dose and 2 from the mid dose group) hit the primary endpoint, with TG levels below the target level of 10 mmol/L or a 40% reduction in TG levels. In two patients of the mid dose group the reduction of TG coincided with expression of active LPL in the injected muscle at 26-32 weeks after vector administration, which clearly demonstrates long-term expression of the therapeutic gene.

Safety

Furthermore, the study shows that AMT-010 was well-tolerated; there were no drug-related severe adverse events, and no dose-limiting toxicity. There was no measurable sign of local or systemic inflammation and no increase in creatinine phosphokinase concentrations, which implies that the impact on tissue function is limited and not harmful to humans.

About AMT

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan diseases. AMT's technology allows long-term gene expression and the specific delivery of therapeutic genes to target organs or tissues. AMT has optimized and validated the production of AAV-based gene therapy vectors. The result is a unique, stable, and scalable GMP production platform. Its lead product, AMT-011, is in pre-registration trials for the first indication: treatment of comp lete LPL deficiency. The company's Management, Supervisory Board and Scientific Advisory Board bring together an extensive know-how of genetics and the biotech and pharmaceutical industries.

For further information, please contact:

AMT:

Ronald Lorijn, CEO

Phone: +31 20 566 7394

Email: r.h.lorijn@amtbv.com

Northbank Communications:

Adam Michael, Account Director

Phone: +44 20 7268 3233

Email: amt@northbankcommunications.com

Holly Griffiths Account Executive ------------------------------------------------------------------------ ----------------------- Direct line: +44 (0)20 7268 3241 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102 www.northbankcommunications.com <http://www.northbankcommunications.com>

Northbank Communications Ltd 85 Tottenham Court Road, London, W1T 4TQ, UK

To see our latest newsletter, Newsbank, please click here <http://www.northbankcommunications.com/newsletter/newsletter.htm> .

This email and any attachments are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient you must not copy this message or any attachment or disclose the contents to any other person. If you have received this message in error please notify the sender immediately and delete this email from your system. Any files attached to this email will have been checked by virus detection software before transmission. You should carry out your own virus checks before opening any email or attachment. Northbank Communications Ltd accepts no liability for any loss or damag e which may be caused by software viruses.

Northbank Communications Limited is registered in England and Wales. Number: 3832764. VAT number: 741277731. Registered office address is Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK.


'"/>




Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Back Pain Centers of America (BPC), which connects people searching ... area, announces the launch of a new and proprietary customer relationship management (CRM) system ... physicians to help them with back or neck pain and helps to match them ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider ... care management module. Using this new feature, sleep physicians can now predict the ... continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
(Date:4/24/2017)... FLORIDA (PRWEB) , ... April 24, 2017 , ... ... telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, ... LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Ridgecrest Herbals ... encourage sustainability, innovate new strategies to reduce waste, and support renewable energy. They believe ... They look to nature to find solutions for health issues, and maintain that destroying ...
Breaking Medicine News(10 mins):